Remedium Capital Partners, LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 12, 2026, for the 2025 Q4 period, Remedium Capital Partners, LLC held in its portfolio 6 assets valued at $170,211 (i.e. $170.21K).

The most valuable assets in the portfolio included: Spyre Therapeutics Inc ($47.71K), Oruka Therapeutics Inc ($47.05K), and Apogee Therapeutics Inc ($44.05K).

The chart below shows the top 6 valuable assets, and the table below shows the top 6 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Remedium Capital Partners, LLC Portfolio

Spyre Therapeutics Inc

Oruka Therapeutics Inc

Apogee Therapeutics Inc

Jade Biosciences Inc

Crescent Biopharma Inc

Galecto Inc

Remedium Capital Partners, LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
Spyre Therapeutics Inc	1456231	47706	COM
Oruka Therapeutics Inc	1552414	47054	COM
Apogee Therapeutics Inc	583591	44050	COM
Jade Biosciences Inc	1577750	24345	COM
Crescent Biopharma Inc	361250	4284	COM
Galecto Inc	120473	2772	COM